(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -9.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Arcus Biosciences's revenue in 2025 is $262,000,000.On average, 5 Wall Street analysts forecast RCUS's revenue for 2025 to be $24,317,349,396, with the lowest RCUS revenue forecast at $23,787,323,136, and the highest RCUS revenue forecast at $24,787,774,310. On average, 5 Wall Street analysts forecast RCUS's revenue for 2026 to be $14,120,623,310, with the lowest RCUS revenue forecast at $7,556,599,296, and the highest RCUS revenue forecast at $20,402,818,099.
In 2027, RCUS is forecast to generate $23,683,340,072 in revenue, with the lowest revenue forecast at $14,027,602,637 and the highest revenue forecast at $35,313,372,113.